AbbVie Inc. Stock (US00287Y1091): Skinvive and CLL data keep the story in focus

AbbVie shares are in focus as fresh Skinvive approval and CLL-14 data add two new catalysts. The stock was last cited at $191.05 in Europe on June 16, 2026, with only a slight daily move.

Responsible: ad hoc news Stocks & Analysis Desk. Reviewed prior to publication on June 16, 2026 at 10:34 PM ET. Details in the imprint.

AbbVie shares are in focus after the company gained a fresh U.S. aesthetic label expansion for Skinvive and highlighted new phase 3 data in chronic lymphocytic leukemia. A market report cited the stock at 191.05 euros on June 16, 2026, with a 0.05% daily decline, which points to a quiet tape rather than a broad re-rating move.

What changed for AbbVie today

Allergan Aesthetics, which is part of AbbVie, said the U.S. Food and Drug Administration approved Skinvive by JuvederM for reducing neck lines in adults 21 and older. The company also said the treatment is the first and only hyaluronic acid injectable with that indication, and it expects commercial availability later in 2026.

That approval matters because it gives AbbVie another visible aesthetic use case beyond the product's prior cheek-smoothing approval in 2023. The same news flow also included phase 3 CLL-14 data on a fixed-duration venetoclax-based combination, which adds a second clinical readout to the day's narrative.

The immediate market message is less about a one-day price shock and more about pipeline breadth. AbbVie already carried a large S&P 500 presence, so incremental label extensions and late-stage oncology updates tend to matter by strengthening longer-term revenue and product-cycle visibility.

In Europe, the stock's cited 191.05-euro level and nearly flat daily change suggest investors did not rush to price in a dramatic near-term change from this news alone. That makes the event useful as a fundamental update, but not as a large-move trading signal.

Key facts on AbbVie stock

• Name: AbbVie Inc.
• Industry: Pharmaceuticals and biotechnology
• Headquarters: North Chicago, Illinois, United States
• Core markets: United States, Europe, and other global pharmaceutical markets
• Revenue drivers: Immunology, aesthetics, neuroscience, oncology, and eye care
• Listing: NYSE: ABBV
• Trading currency: U.S. dollars

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.